Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
25/01/2023 13:45
Jan 25 (Reuters) -
* ANPAC BIO-MEDICAL SCIENCE - IN DEC 2022 AND JAN 2023,
SIGNED
DEFINITIVE INVESTMENT AGREEMENTS WITH SEVERAL THIRD PARTY
INVESTORS
* ANPAC BIO-MEDICAL SCIENCE - INVESTORS AGREED TO PURCHASE
29.7
MILLION NEWLY ISSUED CLASS A ORDINARY SHARES AT
US$0.175/ORDINARY SHARE OR US$3.50/ADS
* ANPAC BIO-MEDICAL SCIENCE - EXPECTS TO USE PROCEEDS FOR
ITS
BUSINESS-TO-BUSINESS ASIAN FOOD E-COMMERCE AND ASIAN FOOD SUPPLY
CHAIN CONSTRUCTION
Source text for Eikon: ID:nGNX65ZQqC
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022